Categories
Press Release

Non Small Cell Lung Cancer Therapeutics Market Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments Forecast to 2026

The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026. Fortune Business Insights has further predicted the market to exhibit an impressive CAGR of 13.4% between 2019 and 2026 due to exceptional advancements in targeted therapy in recent years. Such high growth can be attributable to the increasing demand for chemotherapy and targeted therapy. Furthermore, advantages of targeted therapy over other alternatives are in plenty. Driven by this, the demand for targeted therapy for diagnosis will increase, which in turn spurs growth in the global non-small cell lung cancer therapeutics market.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/non-small-cell-lung-cancer-therapeutics-market-100484

  • Genentech (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp.

Some of the leading companies that are operating in the global non-small cell lung cancer therapeutics market are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), Merck Sharp & Dohme Corp. and others.

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Non Small Cell Lung Cancer by Type
    • Regulatory Scenario by Key Regions
    • Key Industry Developments
    • Pipeline Analysis
    • Overview of Current Advances in R&D for Non Small Cell Lung Cancer Therapeutics
  • Global Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Therapy
      • Targeted Therapy
        • Bevacizumab
        • Dabrafenib/Trametinib
        • Erlotinib Hydrochloride
      • 2.1.4 Osimertinib
        • Others
      • Immunotherapy
        • Durvalumab
        • Nivolumab
        • Atezolizumab
        • Pembrolizumab
      • Chemotherapy
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Market Analysis, Insights and Forecast – By Cancer Type
      • Adenocarcinoma
      • Squamous Cell Carcinoma
      • Large Cell Carcinoma
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa

Schizophrenia Drugs Market USD 9.48 Billion | Hit 4.3% CAGR by 2026 | Fortune Business Insights

Hormone Replacement Therapy Market: 2020 Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

Hepatitis C Testing Market 2020 Global Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast – 2026

Pain Pumps Market Size Worldwide Industry Report | Forecast To 2026

Arthur Siegrist

By Arthur Siegrist

Arthur has nearly a decade of media experience. Before joining FBI Market News, he ran content operations of several local news journals. He also vast experience stock market, corporate communications, public relations, and digital marketing. Arthur holds a commerce degree from the University of Oakland and a post-graduate degree in English from NYU.